SCI Abstract

search
+
Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA
Cost Effectiveness of Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma in the USA
Treating unresectable hepatocellular carcinoma (uHCC) is challenging. Clinical trials have shown that Single Tremelimumab ...
Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia
Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia
Health technology assessment is used extensively by the Pharmaceutical Benefits Advisory Committee (PBAC) to inform medici...
Economic Evaluations of Non-Pharmacological Interventions for Treating Disorders of Gut-Brain Interaction: A Scoping Review
Economic Evaluations of Non-Pharmacological Interventions for Treating Disorders of Gut-Brain Interaction: A Scoping Review
Disorders of gut-brain interaction are highly prevalent and burdensome conditions for both patients and healthcare systems...
A Multistate Model Incorporating Relative Survival Extrapolation and Mixed Time Scales for Health Technology Assessment
A Multistate Model Incorporating Relative Survival Extrapolation and Mixed Time Scales for Health Technology Assessment
Multistate models have been widely applied in health technology assessment. However, extrapolating survival in a multistat...
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review
Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: An Updated Systematic Literature Review
Psoriatic arthritis (PsA) is an inflammatory disease characterised by a variety of clinical manifestations. Considering th...
Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care
Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care
Chimeric antigen-receptor T-cell therapy (CAR-T) is characterised by early phase data at the time of registration, high up...
An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?
An Evaluation of an Algorithm for the Selection of Flexible Survival Models for Cancer Immunotherapies: Pass or Fail?
Accurately extrapolating survival beyond trial follow-up is essential in a health technology assessment where model choice...
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study
China has the highest number of hepatitis C virus (HCV) infections in the world. However, it is unclear what levels of scr...
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias
The National Institute for Health and Care Excellence (NICE) may approve health technologies on condition of more evidence...
MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial
MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial
Survival extrapolation often plays an important role in health technology assessment (HTA), and there are a range of diffe...
Valuation of the EORTC Quality of Life Utility Core 10 Dimensions (QLU-C10D) in a Multi-ethnic Asian Setting: How Does Having Cancer Matter?
Valuation of the EORTC Quality of Life Utility Core 10 Dimensions (QLU-C10D) in a Multi-ethnic Asian Setting: How Does Having Cancer Matter?
The aim of the study was to develop and compare utility value sets for the EORTC QLU-C10D, a cancer-specific utility instr...
Immediate Versus 5-Year Risk-Guided Initiation of Treatment for Primary Prevention of Cardiovascular Disease for Australians Aged 40 Years: A Health Economic Analysis
Immediate Versus 5-Year Risk-Guided Initiation of Treatment for Primary Prevention of Cardiovascular Disease for Australians Aged 40 Years: A Health Economic Analysis
Current Australian cardiovascular disease (CVD) prevention guidelines calculate 5-year CVD risk and recommend treatment wh...
Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukaemia: An External Assessment Group Perspective
Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukaemia: An External Assessment Group Perspective
NICE invited Daiichi Sankyo UK to submit evidence for the clinical and cost effectiveness of quizartinib (Vanflyta®) for t...
Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer
Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer
Capivasertib, a first-in-class AKT inhibitor, was recently approved as a second-line treatment for advanced breast cancer....
How Does Bereavement Affect the Health-Related Quality of Life of Household Members Who Do and Do Not Provide Unpaid Care? Difference-in-Differences Analyses Using the UK Household Longitudinal Survey
How Does Bereavement Affect the Health-Related Quality of Life of Household Members Who Do and Do Not Provide Unpaid Care? Difference-in-Differences Analyses Using the UK Household Longitudinal Survey
Guidelines for modelling in economic evaluation recommend that it may be necessary to consider costs and outcomes until al...
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment
Although innovation generally provides measurable improvements in disease characteristics and patient survival, some benef...
A Framework for the Fair Pricing of Medicines
A Framework for the Fair Pricing of Medicines
As high-cost medicines put increasing pressure on public health care budgets, the need to identify ‘fair’ pric...
Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force
Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force
Omission of family and caregiver health spillovers from the economic evaluation of healthcare interventions remains common...
Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum
Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum
Medical technology is advancing rapidly, but established methods for health technology assessment are struggling to keep u...
Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study
Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study
Antimicrobial resistance is a growing public health concern. There is a global need to estimate the population-level value...
Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective
Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective
Latimer N. NICE DSU Technical Support Document 14: Undertaking survival analysis for economic evaluations alongside clinic...
Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid
Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid
High upfront costs and long-term benefit uncertainties of gene therapies challenge Medicaid budgets, making value-based co...
Evaluating the Quantity and Quality of Health Economic Literature in Blinding Childhood Disorders: A Systematic Literature Review
Evaluating the Quantity and Quality of Health Economic Literature in Blinding Childhood Disorders: A Systematic Literature Review
Evidence on the socioeconomic burden associated with childhood visual impairment, severe visual impairment and blindness (...
The Carer QALY Trap and Altruism in Economic Evaluations
The Carer QALY Trap and Altruism in Economic Evaluations
The idea that carer quality-adjusted life-years (QALYs) should be included as a m...
Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States
Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States
Piflufolastat F 18 is a novel prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PE...
A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects
A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects
A child’s health condition affects family members’ health and well-being. However, pediatric cost-utility anal...
Systematic Review of the Relative Social Value of Child and Adult Health
Systematic Review of the Relative Social Value of Child and Adult Health
We aimed to synthesise knowledge on the relative social value of child and adult health. Quantitative and qualitative stud...
Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A Tutorial
Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A Tutorial
Estimates of costs associated with disease states are required to inform decision analytic disease models to evaluate inte...
Comparative Psychometric Performance of Common Generic Paediatric Health-Related Quality of Life Instrument Descriptive Systems: Results from the Australian Paediatric Multi-Instrument Comparison Study
Comparative Psychometric Performance of Common Generic Paediatric Health-Related Quality of Life Instrument Descriptive Systems: Results from the Australian Paediatric Multi-Instrument Comparison Study
The aim of this study was to compare the psychometric performance of common generic paediatric health-related quality-of-l...
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition
Rising cancer drug prices adversely affect patients’ adherence and survival. We aimed to identify and quantify facto...
Load More
format_indent_increase